Published on : Jun 15, 2016
ALBANY, New York, June 15, 2016: ResearchMoz.us has announced the addition of the “Global Gastric Cancer Market Report: 2016 Edition” report to its offering. This report provides a comprehensive analysis of the market and also comprises the future and the current market competition. A thorough analysis on the prime factors restraining and propelling the growth of the gastric cancer market has been provided in this study. The report also aids in the development of out-licensing and in-licensing strategies by presenting a review of the leading marketed drugs within the gastric cancer market. Additionally, the major opportunities, trends, and the unmet needs of the market during the forecast period 2015 to 2020 have been collated under this report. The companies having a lucrative pipeline are also presented in this report.
The report starts with the market overview section. This section of the report presents the introduction of the market and details the types and stages, prevention, and causes of gastric cancer. In addition, the medical diagnosis and symptoms have also been highlighted in this study. Gastric cancer, also known as stomach cancer is a cancer of the lining of the stomach. The early symptoms of this type of cancer include upper abdominal pain, heartburn, loss of appetite, and nausea. The late stage symptoms include vomiting, weight loss, skin yellowing, blood in stool, and difficulty in swallowing.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=728193
Gastric cancer may also spread to other body parts majorly the lungs, liver, bones, and lymph nodes. A review of the treatment options comes next in the report. These include chemotherapy, surgery, targeted therapy, and radiotherapy. There a number of development taking place in the market for gastric cancer owing to the indolent nature of this disease and poor prognosis. There is a shift towards targeted therapies from chemotherapy and enhanced diagnostic technologies are being employed for the treatment of gastric cancer.
According to the report, the gastric cancer market is majorly fuelled by the rising aging population, the growing obese population, and increasing expending on oncology drugs. In addition, the increasing male population and the rising consumption of cigarettes globally will also add to the growth of the gastric cancer market. The lucrative pipeline of combination targeted therapies and the rising focus on the eradication of Helicobacter pylori (H. pylori) globally are the major trends seen in the market. On the other hand, the absence of reimbursement for cancer drugs and the decreased proliferation of new targeted therapies are the chief factors hampering the growth of the market for gastric cancer.
In the next section of the report, the geographical segmentation for the gastric cancer market has been presented. The U.S., Japan, and the EU 5 countries, namely Germany, Italy, France, the UK, and Spain, are the key dominant countries in the market. In the last section of the report, the major companies dominant in the market have been presented. These are Roche Holdings AG, Merck & Co. Inc., Bristol Myers Squibb, and AstraZeneca Plc., among others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com